Drug intelligence / Profile preview

ASP5834

Development stage: Phase 1
Lead developer: Astellas Pharma
Modality: Small Molecules
Administration: Intravenous

Overview

ASP5834 is an investigational small molecule drug developed for the treatment of various solid tumors, including non-small-cell lung cancer, pancreatic ductal adenocarcinoma, and colorectal cancer. Its exact mechanism of action has not been fully disclosed in public sources. The compound is currently being studied for its pharmacokinetics (how it is processed in the body) and pharmacodynamics (how it acts on the body), with dose-escalation studies focusing on safety and tolerability in adult patients with solid tumors[3][4][6][7][9].

Other names: ASP5834ASP-5834ASP 5834

Targets

KRAS (Kirsten rat sarcoma viral oncogene homolog)

Beyond the preview

Go deeper on ASP5834.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASP5834.

Explore the full profile